Expiration date: 10/2025

Active substance: Umifenovir

Synonyms: Arbidol

Release form, composition and packaging

Tablets, film-coated 1 tablet contains:

ethyl ester 6-bromine-5-hydroxy-1-methyl-4-dimetilaminometil-2-phenylthiomethyl-3-carboxylic acid hydrochloride monohydrate 50 or 100 mg

10 PCs. - packaging sells contoured (1) - packs of cardboard.

10 PCs. - packaging sells contoured (2) - packs of cardboard.

20 PCs. - packaging sells contoured (1) - packs of cardboard.

10 PCs. - packaging sells contoured (3) - packs cardboard.

Clinico-pharmacological group: Antiviral and immunomodulatory drug. Inducer of interferon synthesis

Pharmaco-therapeutic group: Antiviral immunostimulatory agent

Testimony

Prevention and treatment in adults and children:

  • the flu, caused by viruses A and b;
  • acute respiratory viral infections (ARVI) (including complicated bronchitis, pneumonia);
  • secondary immunodeficiency states.

Complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection.

Posleoperazionny prevention of infectious complications and the normalization of the immune status in adults.

The dosage regimen

Inside, before meals. Single dose: children from 3 to 6 years 50 mg, 6-12 years - 100 mg, over 12 years and adults - 200 mg (2 tablets of 100 mg or 4 tablets of 50 mg).

For nonspecific prevention

In direct contact with patients with influenza and other viral respiratory infection: children from 3 to 6 years 50 mg, 6-12 years - 100 mg, over 12 years and adults - 200 mg 1 time a day for 10-14 days.

During the epidemic of influenza and other respiratory, for the prevention of exacerbations of chronic bronchitis, recurrence of herpetic infection: children from 3 to 6 years 50 mg, 6-12 years - 100 mg, over 12 years and adults - 200 mg 2 times per week for 3 weeks.

Prophylaxis of postoperative complications: children from 3 to 6 years 50 mg, 6-12 years - 100 mg, over 12 years and adults - 200 mg 2 days before surgery, then at 2 and 5 days after the surgery.

For the treatment of

Influenza and other ARVI without complications: children from 3 to 6 years 50 mg, 6-12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5 days.

Influenza and other ARVI with the development of complications (bronchitis, pneumonia, and others): children from 3 to 6 years 50 mg, 6-12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5 days, then a single dose 1 time per week for 4 weeks.

Side effects

Allergic reactions.

Contraindications

  • children's age (up to 3 years);
  • the presence of diseases such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption;
  • hypersensitivity to the drug.

The children

Contraindicated in children up to 3 years.

Special instructions

Does not show the Central neurotropic activity and can be used in medical practice as a preventive measure in healthy persons of various professions, including requiring attention and coordination of movements (drivers, operators, and so on).

Overdose

Not marked.

Drug interactions

In the appointment with other drugs negative side effects were not observed.

Arpeflu
(Umifenovir)